Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company focused on endocrinology and rare diseases, with its primary political exposure stemming from eight pending healthcare bills each estimated to impact revenue by ~$5M.
BusinessWhat ASND does
Ascendis Pharma A/S is a late-stage biopharmaceutical company developing product candidates for rare endocrine diseases and endocrine-related cancers using its TransCon technology platform. Its commercial portfolio includes treatments for growth hormone deficiency and hypoparathyroidism, with revenue derived from product sales and collaboration agreements. The company's pipeline is heavily dependent on FDA regulatory pathways and reimbursement policies.
12 months past · 3 months futureASND activity timeline
Lifetime Government AwardsASND federal contracts
ASND doesn't hold direct federal contracts.
Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.
Smart Money · 13F HoldingsHedge funds holding ASND
Congressional TradesWho in Congress is trading ASND
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
No Form 4 activity recorded in the last 180 days.
Bills Affecting ASNDLive legislation impacting this stock
Political ProfileWhere ASND sits in Washington
[object Object]
STRUCTURAL: High regulatory density (score 90) and government dependence (score 85) due to healthcare sector and pending legislation. EVIDENTIARY: No direct political engagement: $0 lobbying (`get_political_influence.lobbying.total_income`), 0 corporate insider buys (`get_corporate_insider_signal.total_buys`), 0 congressional traders (`Top congressional traders`), and $0 federal contracts (`get_government_precedent.federal_contracts_summary`). Net: High structural exposure is entirely unmitigated by evidentiary support, creating a neutral but fragile signal.
Regulatory ExposureThreats & opportunities
Regulatory threats
-
Potential revenue impact from multiple pending healthcare bills affecting drug pricing or market access.Congress"`Recent bill_impacts` lists eight bills with uniform impact_ratio of 0.0004 and estimated revenue impacts averaging ~$5.1M."
Regulatory opportunities
-
Legislative action could standardize or expedite reimbursement for rare disease therapies.Congress"`Recent bill_impacts` indicates multiple bills in the healthcare sector directly modeling revenue impact for the company."
Live signals + predictions for ASND — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades ASND
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord